Thermo Fisher Scientific (TMO) reported $11.12 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 4.9%. EPS of $5.79 for the same period compares to $5.28 a year ago.
The reported revenue represents a surprise of +1.99% over the Zacks Consensus Estimate of $10.91 billion. With the consensus EPS estimate being $5.50, the EPS surprise was +5.27%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Thermo Fisher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue Growth - Organic: 3% versus 2.7% estimated by six analysts on average.
- Revenues- Laboratory Products and Biopharma Services: $5.97 billion compared to the $5.93 billion average estimate based on four analysts. The reported number represents a change of +4% year over year.
- Revenues- Specialty Diagnostics: $1.17 billion compared to the $1.16 billion average estimate based on four analysts. The reported number represents a change of +4% year over year.
- Revenues- Life Sciences Solutions: $2.59 billion versus $2.47 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +8.4% change.
- Revenues- Eliminations: $-503 million versus $-487.37 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.7% change.
- Revenues- Analytical Instruments: $1.89 billion versus the four-analyst average estimate of $1.8 billion. The reported number represents a year-over-year change of +4.7%.
View all Key Company Metrics for Thermo Fisher here>>>
Shares of Thermo Fisher have returned +18.8% over the past month versus the Zacks S&P 500 composite's +1.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
